4.2 Review

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

Journal

PHARMACOGENOMICS
Volume 10, Issue 1, Pages 59-68

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/14622416.10.1.59

Keywords

cancer genetics; EGFR; lung cancer; predictive markers

Funding

  1. NIH [R01CA92824, R01CA074386, K12 CA087723]
  2. NATIONAL CANCER INSTITUTE [R01CA092824, K12CA087723, R01CA074386] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available